Enzo Ventures invests in Cori Clinical
Funding Provisional 78% confidence first seen
Enzo Ventures, via its newly launched €20 million pre-seed Fund II, invested in Cori Clinical in London as one of its early portfolio companies. The article does not provide deal size or specific investment terms, but notes that Fund II is expected to make first checks of roughly €250,000 to €600,000. This matters because it signals Enzo extending its Southern Europe–focused pre-seed strategy to companies outside the region while keeping its emphasis on early-stage B2B/AI/software founders.
The deal
Cori Clinical Undisclosed Seed · announced 19 Oct 2026
Investors Enzo Ventures
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Enzo Ventures launched a €20 million pre-seed Fund II and identified Cori Clinical in London as one of its first portfolio companies. The coverage says the fund plans initial checks of roughly €250,000 to €600,000, but it does not disclose Cori Clinical’s specific round size or terms.
- Why it matters
- For leaders tracking early-stage AI and software financing, this indicates that Enzo is actively deploying fresh pre-seed capital and is willing to back companies outside Southern Europe if they fit its founder and sector thesis. That can modestly widen the pool of active seed-stage capital for London-based B2B/AI/software startups and suggests geography may be becoming less rigid than incorporation location in some early-stage fundraising decisions.
- Evidence
- The claim is supported by a single Tech Funding News AI article reporting that Enzo Ventures launched Fund II at €20 million and that Cori Clinical in London is already among three investments. The same report states the fund will write first checks of €250,000 to €600,000 and focus on B2B technology, AI, and software rather than incorporation geography.
- What remains uncertain
- The article does not confirm Cori Clinical’s exact sector positioning, the amount Enzo invested, round participants, valuation, or whether Cori Clinical fits the AI focus specifically versus broader software/health tech. Because coverage comes from one outlet and lacks deal terms, any conclusions about competitive fundraising dynamics or Enzo’s long-term geographic expansion should be treated as provisional.
- Monitor next
- Watch for a company or investor announcement disclosing Cori Clinical’s round size, co-investors, and product category.
Analytical support, not advice — assumptions and open questions stated above.